Overview

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and how well giving autologous T cells with cyclophosphamide works in treating patients with soft tissue sarcoma that is metastatic or cannot be removed by surgery. Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving autologous T cells together with cyclophosphamide may kill more tumor cells.

Phase:

Phase 1

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cyclophosphamide